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Abstract 
A~-Piperidine-2-carboxylic acid (P2C), an intermediate of the L-lysine metabolic pathway in the brain, was studied for its uptake and 
metabolism in the synaptosome of the rat cerebral cortex. The results of this study showed that the uptake of P2C into the synaptosome 
was NA+-and temperature-dependent with a two-tier transport kinetic (Km = 2.6 and 0.7/xM; Vma × = 1.6 and 0.73 pmol/min/mg). P2C 
uptake was only moderately inhibited (= 20%) by L-lysine and its metabolites, L-pipecolic acid and L-a-aminoadipic acid at up to 100 
/xM, and the putative amino acid neurotransmitters, y-aminobutyric a id, L-glutamic acid and L-aspartic acid (25-31%) at 5-500 /.~M. 
The synaptosomal preparation only has a very low activity for metabolizing P2C to its product L-pipecolic acid. The metabolic activity for 
P2C was mainly contained in the 27000 x g supernatant S 2 fraction. Since P2C is the precursor of the putative neuromodulator 
L-pipecolic acid, the understanding of its uptake and metabolic haracteristics in the brain should be of significance. 
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1. Introduction 
At-Piperidine-2-carboxylic a id (P2C; the cyclic form 
of a-keto-e-aminocaproic a id) is an intermediate of L- 
lysine metabolism through the pipecolic acid pathway 
which is different from the more familiar pathway involv- 
ing saccharopine (~-N-(glutaryl-2)-L-lysine) as a first prod- 
uct [1]. An L-amino acid oxidase L-amino acid: 0 2 oxido- 
reductase (deaminating) from the microsome of chicken 
liver [2] and an L-lysine dehydrogenase L-lysine: nicotin- 
amide-adenine dinucleotide (NAD)-ox idoreductase 
(deaminating) from the soluble fraction of human liver 
homogenate [3] have both been reported to metabolize 
L-lysine to P2C. In bacteria, however, P2C appears to be a 
product of o-lysine metabolism [4]. A nucleotide-linked 
enzyme, P2C reductase (L-Pipecolic acid: NAD (NADP) 2- 
oxidoreductase) responsible for the conversion of P2C to 
L-pipecolic acid has been described in both the mammals 
[5] and the bacteria [6]. In our preliminary study we have 
characterized and purified this enzyme to near homogene- 
ity and it will be submitted for publication in the near 
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future. Measurement of Al-pyrroline-2-carboxylate reduc- 
tase activity taken as pipecolic acid formation exhibits 
considerable regional differences in the central nervous 
system of the mouse, dog and monkey [7]. The regional 
distribution of the enzyme P2C reductase which is an 
actual precursor of pipecolic acid has not so far been 
studied. 
L-Pipecolic acid has been shown to be a major product 
of L-lysine metabolism in the animal and human brains 
[8-10] with many neurological studies been reported [11- 
16]. The uptake and release of 7-aminobutyric acid 
(GABA) have been shown to be influenced by pipecolic 
acid [17-19]. In addition, pipecolic acid has been shown to 
modulate GABA binding of GABA to its brain membranes 
in the presence of barbiturates [20], and it also has a 
specific binding to the brain membranes [21]. However, 
despite P2C is a precursor of L-pipecolic acid, perhaps 
because P2C is not commercially available, no transport or 
neurochemical study has so far been reported. We report 
here a study which concerns the metabolism and uptake of 
P2C by the synaptosome-enriched fraction (P3) prepared 
from the rat cerebral cortex. The effects of other lysine 
metabolites and putative amino acid neurotransmitters, 
GABA, L-glutamate and L-aspartate, on the uptake have 
also been investigated. 
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2. Experimental procedures 
2.1. Materials 
L-[l-14C]Lysine was obtained from New England Nu- 
clear Corporation; L-lysine, L-pipecolic acid, DL-pipecolic 
acid, DL-a-aminoadipic a id, L-aspartic acid and L-glutamic 
acid from Sigma; 7-aminobutyric acid from Mann Re- 
search Laboratories; D-amino acid oxidase (EC 1.4.3.3) 
from Sigma; Dowex 50 (H ÷) from Bio-Rad Laboratories; 
Hydromix from Yorktown Research. 
2.2. Preparation of synaptosome-enriched P3 fraction 
Synaptosome-enriched P3 fraction was prepared from 
the cerebral cortex of male Sprague-Dawley rats (150-200 
g) according to a method combining the procedures of 
Wheeler [22] and Tamir et al. [23]. In general, the cerebral 
cortex (excluding mesencephalon, pons, and medulla) from 
rats was homogenized in 10 volumes of ice-cold 0.32 M 
sucrose by a glass tissue grinder equipped with a Teflon 
pestle driven by a motor at 650 rpm for 10-15 strokes. 
The homogenates were centrifuged at 1000 × g for 10 min 
to remove the nuclei and other cell debris (P1). The 
supernatant (Sl) was centrifuged again at 27 000 × g for 
15 min to obtain the synaptosome-mitochondria-myelin 
pellet (P2)- The supernatant fraction (S 2) was saved for 
metabolism study. The P2 fraction after suspension i  0.32 
M sucrose was layered onto a discontinuous sucrose gradi- 
ent prepared from 8 ml each of 0.8 and 1.2 M sucrose in 
half-strength Krebs-Ringer solution free of Ca 2+. After 
centrifugation at55 000 X g for 60 min, the synaptosome- 
enriched P3 fraction was recovered in the 0.8 M sucrose 
layer. 
2.3. Synthesis of [1-14 C]P2C 
the ingredients in mM: NaC1, 127.2; KC1, 5.0; MgSO 4, 
1.3; CaC12, 2.7; Tris, 25.0) for 5 min at 37°C. At the end 
of the incubation, P2C uptake was stopped by filtration 
through a Reeve Angel (Whatman) 934 AH glass filter 
(2.4 cm diameter) on a Hoefer vacuum filtration manifold. 
The filter was washed twice, each with 5 ml cold buffer. 
The dried filter with the retained synaptosomes was mixed 
with Hydromix and assayed for radioactivity in a Packard 
2425 liquid scintillation spectrometer. The counting effi- 
ciency of the samples was estimated by the use of auto- 
matic external standardization. For the assay of P2C up- 
take at various concentrations, unlabeled P2C was added to 
obtain the desired concentrations. To test dependency of 
P2C uptake on Na +, Na ÷ ions were replaced by Tris in the 
Krebs-Henseleit buffer to maintain a constant osmolarity. 
2.5. Metabolism of [1-14C]P2C 
[1-14C]P2C (0.2 Ci) was incubated with the cerebral 
cortex crude homogenate, the S 2 or the P3 fraction (each 
containing approx. 1 mg protein) at 37°C for 60 min in a 
final volume of 1 ml. After the incubation the mixtures 
were extracted with 4 volumes of 0.4 M perchloric acid. 
After neutralization with 0.4 M KOH and removal of 
precipitated perchlorate by centrifugation, the supernatant 
solution was flash evaporated to dryness under reduced 
pressure at 50°C. The residues dissolved in 0.01 M HC1 
were analyzed by a Technicon amino acid analyzer 
equipped with a Durrum DC-1A Column as described 
previously [8,9]. The column was eluted with buffers B 
and C of Pico-Buffer II (Pierce) programmed for 35 and 
100 min, respectively. The column effluent collected by a 
fraction collector was counted for radioactivity as de- 
scribed previously [8,9]. Characterization f pipecolic acid 
and a-aminoadipic acid, the reaction products of P2C, was 
by means of amino acid analysis and paper chromatog- 
raphy as previously described [8,9,25,26]. 
[1-14C]P2C (300 Ci/mol) was synthesized from OL-[1- 
~4C]pipecolic acid by exhaustive oxidation of the latter 
compound with o-amino acid oxidase as described previ- 
ously [25]. DL-[1-14C]Pipecolic acid was prepared from 
L-[1-t4C]lysine according to the method of Rodwell [24] as 
described previously [25]. Unlabeled P2C was prepared 
from DL-pipecolic acid similar to that of the labeled P2C 
[25]. Both labeled and unlabeled P2C were dissolved in 
0.01 M HCI and kept frozen. The compound was neutral- 
ized immediately before use. 
2.4. Uptake of [1-14C]P2C by synaptosomes 
A standard assay of P2C uptake was conducted by 
incubating 0.1 ml [I-14C]P2C (0.5 M, 1.00 Ci/ml) with 
0.2 ml synaptosome preparation (P3) (0.2-0.5 mg/ml) in 
3.7 ml of Krebs-Henseleit buffer, pH 7.4 (concentration f 
3. Results 
3.1. Uptake of [1-14 C]P2C by synaptosomes 
The uptake of P2C by the synaptosomes of rat cerebral 
cortex was proportional to the incubation time (Fig. 1). 
The rate of this uptake remained linear in relation to the 
incubation time for up to 5 min under the experimental 
conditions described. The maximal tissue-medium ratio of 
approx. 3.6 was attained after 10 min of incubation. 
The rate of synaptosomal uptake of P2C was tempera- 
ture-dependent with a Q10 value of 1.2 (Fig. 2). The 
transport of P2C was only partially Na+-dependent (Table 
1). Even in the absence of Na ÷, the synaptosomal P2C 
uptake rate was still 63% of that when Na + concentration 
was 127.2 mM. 





I I I I 
0 5 10 15 20 
TIME, min. 
Fig. 1. Time-course of accumulation labeled P2C into rat cortical synap- 
tosome. Experiment was conducted as in the standard assay except hat 
samples were taken at time intervals as shown. Results are means ± S.E. 
from quadruplicate measurements. 
Table I 
Dependency of P2C uptake into synaptosome on sodium ion 
NaCI P2C uptake Uptake rate 
(raM) (pmol/mg synaptosome) (%) 
127.2 1.49+0.03 100_+ 1.9 
50 1.06 ± 0.04 71.14- 2.4 
20 1.06±0.05 71.1 ±3.6 
0 0.94 + 0.04 62.9 ± 2.7 
P2C uptake was measured as described in the standard assay except hat 
NaCI was replaced with equivalent amounts of Tris in the Krebs Henselit 
buffer when NaCI concentration was reduced from 127.2 mM. Values are 
means + S.E. from quadraplicate xperiments. 
3.2. Kinetics of [1-14 C]P2C uptake into synaptosomes 
Kinetic analysis of the uptake of P2C into synapto- 
somes was done by the double reciprocal plot of 
Lineweaver and Burk [27] as presented in Fig. 3. The K m 
values calculated by the least square fit for the uptake of 
P2C were found to be 2.6 M and 0.74 /zM. The Vma x 
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Fig. 2. Temperature dependency of labeled P2C uptake into rat cortical 
synaptosome. Experiment conditions were as those in the standard assay 
except hat incubation was conducted at temperatures shown. Values are 
means ± S.E. from quadruplicate measurements. 
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Fig. 3. Kinetic analysis of the uptake of labeled P2C into rat conical 
synaptosome. Experimental conditions were same as those for the stan- 
dard assay. Values are means + S.E. of four measurements. The lines 
represent double reciprocal plots of Lineweaver and Burk of the com- 
puted least square fit. V: pmol/5 min/mg. 
Table 2 
Effect of L-lysine, L-pipecolate and L-a-aminoadipate on the uptake of P2C into synaptosome 
Effector concentration (/zM) L-Lysine L-Pipecolic acid L-a-Aminoadipic acid 
pmol/mg inhibition % pmol/mg inhibition % pmol/mg inhibition % 
0 1.44 ± 0.15 - 1.44 + 0.15 - 1.44 + 0.15 - 
5 1.11 + 0.05 23.1 _ 3.7 1.15 + 0.02 20.2 ± 1.5 1.15 ± 0.05 20.4 + 3.3 
50 1.14 ± 0.08 21.3 ± 5.8 1.15 ± 0.06 20.5 + 3.9 NA NA 
100 1.06 ± 0.06 26.9 ± 4.4 1.26 + 0.08 12.6 _+ 5.2 NA NA 
100 0.99 -i- 0.06 31.5 _ 4.1 1.22 ___ 0.07 15.7 ± 4.8 1.19 ± 0.09 17.3 4- 6.5 
NA denotes "not assayed'. 
P2C uptake was measured as described in the standard assay except hat NaCI was replaced with equivalent amounts of Tris in the Krebs Henselit buffer 
when NaCI concentration was reduced from 127.2 mM. Values are means ± S.E. from quadraplicate xperiments. 
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Table 3 
Effect of GABA, L-glutamate and L-aspartate onuptake of P2C into synaptosome 
Effector concentration (/xM) GABA L-Glutamate L-Aspartate 
pmol/mg inhibition % pmol/mg inhibition % pmol/mg inhibition 
0 1.49 _+ 0.03 - 1.49 _ 0.03 - 1.49 + 0.03 - 
5 1.11 -4- 0.04 25,4 + 2.5 1.03 + 0.05 30.5 + 3.2 1.09 + 0.04 26.6 + 5.4 
50 1.32 + 0.02 l 1.5 + 1.5 NA NA NA NA 
100 1.26 + 0.13 15.1 _ 8.5 1.29 -t- 0.17 13.5 + 11.6 1.19 _ 0.07 19.7 + 4.8 
500 1.20 ___ 0.04 19.1 + 2,9 1.16 _ 0.05 21.9 _+ 3.2 1.11 ± 0.06 25.5 +__ 4.2 
NA denotes 'not assayed'. 
P2C uptake was measured as described in the standard assay except that NaCI was replaced with equivalent amounts of Tris in the Krebs Henselit buffer 
when NaCI concentration was reduced from 127.2 raM. Values are means + S.E. from quadraplicate experiments. 
values obtained from this analysis were 1.6 pmol /min /mg 
and 0.73 pmol /min /mg.  
3.3. Effect of lysine metabolites, GABA, L-glutamate and 
L-aspartate on the uptake of P2C 
P2C uptake into synaptosomes was inhibited 20 to 23% 
by L-lysine and two of its metabolic intermediates, L-
pipecolic acid and L-a-aminoadipic acid at 5 /zM (Table 
2). This inhibition was increased to about 32% by L-lysine 
at 0.5 mM. The increase of L-pipecolate and L-ot- 
aminoadipate concentrations not only did not increase but 
slightly reduced their inhibition on P2C uptake. 
At 5 p~M GABA inhibited P2C uptake by 25% while 
L-glutamic acid and L-aspartic acid by 31 and 27%, respec- 
tively (Table 3). The increase of the concentration of 
GABA and L-glutamate to 0.5 mM, however, slightly 
reduced their inhibition on P2C uptake. 
3.4. Metabolism of P2C 
Very active metabolism of P2C was observed in the 
crude homogenate of rat cerebral cortex and the 27 000 X g 
Table 4 
Metabolism of [1-~4C]P2C by crude homogenate (27000× g) super- 
natant (S 2) and synaptosome (P3) fractions of the rat cerebral cortex a 
Preparation % Radioactivity recovered 
P2C piecolate other metabolites b 
Crude homogenate 29.3 51.5 19.2 
S 2 L6 94.3 4.1 
P3 93.5 2.6 3.9 
a 0.2 Ci of [1-t4IP2C was incubated with the crude cerebral cortex 
homogenate (27000× g) supernatant (S 2) or the synaptosome (P3) frac- 
tion for 60 min at 37°C as described inthe Experimental procedures. The 
incubation mixtures were extracted and analyzed by an amino acid 
analyzer as described. The overall recovery of radioactivity was approx. 
70% of the starting material for every incubation. 
b 'Other metabolites' refer to metabolic products of P2C other than 
pipecolic acid. These metabolites include ot-aminoadipic acid and other 
compounds which are not yet clearly characterized. 
supernatant (S 2) (Table 4). After 60 min of incubation 
51.5% of the starting material was converted to pipecolic 
acid by the crude homogenate, and 94.3% by the S 2 
fraction. Other metabolic products of P2C were also de- 
tected in these two incubation mixtures. These products 
include a-aminoadipic acid and other uncharacterized 
metabolic intermediates which amount o about 19 and 4% 
of the total recovered radioactivity in the crude ho- 
mogenate and S 2 incubations, respectively (Table 4). The 
synaptosomal fraction (P3) has only very low activity of 
P2C metabolism. After 60 min of incubation, more than 
93% of P2C was recovered with less than 3% of the 
starting material being converted to pipecolic acid, and 
about 4% to other metabolic products. 
4. Discussion 
P2C displayed a temperature-and Na+-dependent uptake 
by the synaptosome-enriched fraction (P3) of the rat cere- 
bral cortex, suggesting that this uptake is most likely a 
specific rather than a diffusional mechanism. The depen- 
dency on Na ÷ for P2C uptake appears to be much less 
than that for the putative amino acid neurotransmitters 
L-glutamate and L-aspartate [28], or that for L-a- 
aminoadipate [29], another intermediate of the iysine 
metabolic pathway in the brain. It should be noted that the 
uptake of pipecolic acid, another lysine metabolite of 
neurological interest [13], is only partly inhibited when 
Na ÷ concentration is lowered. 
P2C uptake into the rat cortical synaptosomes appears 
to display an unusual two-tier transport kinetic (Fig. 3). 
Since both g m values are very low (0.74 and 2.6 /xM), 
they represent the high-affinity, low-capacity uptake. The 
reason that the low-affinity transport is not apparent for 
P2C might be due to masking by the high affinity uptake 
as reported by Davies and Johnson for D-aspartic uptake 
[30]. On the other hand, it is interesting to note that other 
lysine metabolites pipecolic acid and a-aminoadipic acid 
display a clear high- and low-affinity uptake [15,29]. 
The uptake of P2C is only partially inhibited by other 
Y.-F. Chang, A.K. Charles /Biochimica et Biophysica Acta 1238 (1995) 29-33 33 
lysine intermediates and other amino acids tested (Table 2 
and Table 3). Since the level of inhibition by either the 
alicyclic compound (i.e., L-pipecolic acid) or the aliphatic 
compounds (i.e., L-lysine and L-a-aminoadipic acid) are 
not much different, it suggests that there is no preference 
of P2C been transported in the cyclic form (i.e., A l- 
piperideine-2-carboxylic acid) or in the aliphatic form 
(a-keto-(-aminocaproic acid). However, since the trans- 
port of an amino acid usually can be inhibited by several 
compounds with different degrees of structural similarity 
[31], the phenomenon observed above may be another 
example of low specificity inhibition common in amino 
acid transport. On this basis, it is interesting to note that 
proline, a close analog of pipecolic acid, at the concentra- 
tion of 10 -4 M inhibits pipecolic acid uptake by synapto- 
somes from mouse brain by 50% [15]. 
Active metabolism of P2C to pipecolic acid was ob- 
served in the crude homogenate and supernatant fraction 
(S 2) of rat cerebral cortex (Table 4). The slight activity of 
P2C metabolism to pipecolic acid and other metabolites 
observed in the P3 fraction might be due to either a 
contamination of the S 2 fraction or the presence of P2C 
reductase inside the synaptosomes. The latter possibility is 
currently under investigation. As expected this conversion 
is most effective in the supernatant fraction since P2C 
reductase has been shown earlier to be a soluble enzyme 
both in the animals in our preliminary study mentioned 
above and in the bacteria [6]. Pipecolic acid is known to be 
metabolized to a-aminoadipic acid in the rat [8,9] and in 
the human and monkey [10]. This may explain the pres- 
ence of a-aminoadipic acid and other metabolites in the 
incubation mixtures of the crude homogenate and the S 2 
fraction when P2C was the substrate. 
As noted by us previously [25], P2C is quite unstable. It
polymerizes readily under storage at room temperature at
neutral pH [25]. No P2C has yet been detected in the living 
system, indicating its transitory status as an intermediate in 
the lysine metabolic pathway, and its unstable nature. 
However, in view of the fact that the metabolic system for 
P2C is present as P2C reductase has been identified, 
purified and characterized in our preliminary study. P2C is 
actively taken up by the synaptosomes of rat brain, and 
that this uptake is influenced by other putative amino acid 
neurotransmitters as described in the present article, un- 
doubtedly the uptake and metabolism of P2C play a signif- 
icant role in neuronal function which has yet to be fully 
elucidated. More importantly P2C is the precursor of the 
putative neuromodulator L-pipecolic acid. The catabolism 
of pipecolate is defective due to the dysfunction of the 
peroxisomes. Several neurological diseases such as the 
hyperpipecolatemia, adrenoleukodystrophy and the cere- 
brohepatorenal syndrome of the Zellweger's (for review 
see Ref. [32]) are known to exist. Further study and 
understanding of P2C transport and its neurochemical 
characteristics are warranted. 
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